Clinical trials: Diabetes, Type 1
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The purpose of this trial is to compare the pharmacokinetic properties (the exposure of the trial drug in the body) of different formulations of NN1218.
- Trial name
- NCT01469143
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
T1DM - Type 1 Diabetes Mellitus
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
The purpose of the investigation is to evaluate the performance of the I3 CGM in Pediatric Patients with Type 1 Diabetes Mellitus (T1DM) according to the FDA's special controls for iCGM.
- Trial name
- NCT05908448
- Testing
- 13 CGM (continuous glucose monitor)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Sinocare
Type 2 Diabetes Mellitus
To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
This is an open-label, randomised study to compare the similarity of a combination Dapagliflozin/Metformin tablet with the two drugs administered separately under fasting and fed conditions in healthy volunteers.
- Trial name
- NCT01535677
- Testing
- Dapagliflozin + Glucophage tablet fasted, Dapagliflozin/metformin IR FDC tablet fasted, Dapagliflozin + Glucophage tablet fed
- Where
- United Kingdom
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Glucose, Low Blood, Glucose, High Blood
Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC
The objective of this study is to test two different operating modes of the latest version of the Dose Safety artificial pancreas system (APS), the Dose Safety Controller (DSC version 2.3), in a population of subjects with type 1…
- Trial name
- NCT03428295
- Testing
- Dose Safety AP system
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dose Safety Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
This trial is conducted in Europe. The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir.
- Trial name
- NCT00435019
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 43 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 348 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Diabetes Mellitus Type 1
Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages
The ultimate goal of the PCDIAB project is to develop a bi-hormonal pump (insulin and glucagon) substituting for the pancreas and facilitating tight euglycemic control in patients with T1DM.
- Trial name
- NCT01916265
- Testing
- Glucagon
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type 2 Diabetes Mellitus (T2DM), Obesity
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple escalating oral doses of PF-06954522 in adult participants with inadequately controlled type 2 diabetes…
- Trial name
- NCT06279234
- Testing
- Rosuvastatin, Midazolam, Omeprazole
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sleep EEG
EEG Changes of type1 Diabetes During Sleep -Insulin Induced Hypoglycemia
Hypoglycaemia is associated with characteristic changes in the EEG with the appearance of slow frequency waves. In a recent study the investigators have shown that these changes can be recorded from subcutaneous electrodes and…
- Trial name
- sleep (NCT01237509)
- Testing
- Hypo device
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- UNEEG Medical A/S
Type 1 Diabetes, Type 2 Diabetes
To Evaluate the Efficacy and Safety of the Insulin Patch Pump System in Patients With Diabetes.
Patients will be enrolled and randomly assigned to either the test group or the control group for short-time intensive insulin therapy in inpatient setting.
- Trial name
- NCT07403565
- Testing
- Insulin Patch Pump System, Minimed 700
- Where
- 5 sites in China
- Volunteers
- 161 people
- Sponsor
- Suzhou Hechun Medical Technology Co., Ltd.
Type 1 Diabetes Mellitus
Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate similarity in pharmacokinetics (PK) of SAR341402 and NovoLog after 4x4-week periods of alternating administration of SAR341402 and NovoLog compared to 16-week continuous use of NovoLog in…
- Trial name
- GEMELLI X (NCT03874715)
- Testing
- Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100
- Where
- 33 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Primary objective : To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then after 13 weeks \& at the end of the study which will be after 26 weeks) in subjects with type I diabetes mellitus.
- Trial name
- GLANS (NCT00539448)
- Testing
- insulin glargine, insulin glulisine
- Where
- 4 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 98 people
- Sponsor
- Sanofi
Type 2 Diabetes
Naturlose (D-Tagatose) Efficacy Evaluation Trial
The purpose of this trial was to evaluate the effectiveness and safety of Naturlose (Tagatose) for glycemic control in people with Type 2 diabetes who were not taking other medications for the condition and who were under diet…
- Trial name
- NEET (NCT00955747)
- Testing
- Tagatose, Sugar Substitute Splenda
- Where
- 46 sites in United States, India
- Volunteers
- 494 people
- Sponsor
- Robert Lodder
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 640G Insulin Pump
This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia.
- Trial name
- NCT01991548
- Testing
- MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial
A 6-week crossover study will compare PLGS to SAP outcomes in adults and youth > 6 years old with type 1 diabetes (T1D).
- Trial name
- NCT03195140
- Testing
- Predictive Low Glucose Suspend
- Where
- 4 sites in United States
- Volunteers
- 103 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
- Trial name
- NCT00134147
- Testing
- Inhaled Insulin
- Where
- 121 sites in United States, Canada and 5 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Type 1 Diabetes
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
This is a single-centre, randomised, double-blind, 4-way crossover, 4-treatment, euglycaemic clamp study in subjects with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT04501107
- Testing
- Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1), Administration of Ready-to-use BioChaperone insulin lispro (IMP2), Administration of US-approved Humalog® (IMP3)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Adocia
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desired level of glycemic control…
- Trial name
- NCT00108004
- Testing
- pramlintide acetate
- Where
- 48 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.